Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Efficacy of initial Basal-supported oral therapy with sitagliptin in untreated type 2 diabetes.

Yoshioka K.

Diabetes Ther. 2013 Dec;4(2):409-16. doi: 10.1007/s13300-013-0043-x.

2.

Efficacy and safety of switching from basal insulin to sitagliptin in Japanese type 2 diabetes patients.

Harashima SI, Tanaka D, Yamane S, Ogura M, Fujita Y, Murata Y, Seike M, Koizumi T, Aono M, Wang Y, Inagaki N.

Horm Metab Res. 2013 Mar;45(3):231-8. doi: 10.1055/s-0032-1323763.

PMID:
22972180
4.

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.

Williams-Herman D, Johnson J, Teng R, Luo E, Davies MJ, Kaufman KD, Goldstein BJ, Amatruda JM.

Curr Med Res Opin. 2009 Mar;25(3):569-83. doi: 10.1185/03007990802705679 .

PMID:
19232032
5.

Basal-Supported Oral Therapy with Sitagliptin Counteracts Rebound Hyperglycemia Caused by GLP-1 Tachyphylaxis.

Meguro S, Kawai T, Matsuhashi T, Sano M, Fukuda K, Itoh H, Suzuki Y.

Int J Endocrinol. 2014;2014:927317. doi: 10.1155/2014/927317.

6.

Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes.

Asai S, Ohta A, Kato H, Sada Y, Nagai Y, Kondo A, Sasaoka T, Tanaka Y.

Endocr J. 2014;61(12):1213-20. doi: 10.1507/endocrj.EJ14-0194.

7.

Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes.

Wainstein J, Katz L, Engel SS, Xu L, Golm GT, Hussain S, O'Neill EA, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 May;14(5):409-18. doi: 10.1111/j.1463-1326.2011.01530.x.

PMID:
22059736
8.

Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.

Tang YZ, Wang G, Jiang ZH, Yan TT, Chen YJ, Yang M, Meng LL, Zhu YJ, Li CG, Li Z, Yu P, Ni CL.

Diabetol Metab Syndr. 2015 Oct 19;7:91. doi: 10.1186/s13098-015-0087-3.

9.

Sitagliptin versus mitiglinide switched from mealtime dosing of a rapid-acting insulin analog in patients with type 2 diabetes: a randomized, parallel-group study.

Takeshita Y, Takamura T, Kita Y, Takazakura A, Kato K, Isobe Y, Kaneko S.

BMJ Open Diabetes Res Care. 2015 Aug 28;3(1):e000122. doi: 10.1136/bmjdrc-2015-000122.

10.

A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.

Olansky L, Reasner C, Seck TL, Williams-Herman DE, Chen M, Terranella L, Mehta A, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2011 Sep;13(9):841-9. doi: 10.1111/j.1463-1326.2011.01416.x.

PMID:
21535346
11.

Effectiveness of basal-supported oral therapy (BOT) using insulin glargine in patients with poorly controlled type 2 diabetes.

Suzuki D, Umezono T, Miyauchi M, Kimura M, Yamamoto N, Tanaka E, Kuriyama Y, Sato H, Miyatake H, Kondo M, Toyoda M, Fukagawa M.

Tokai J Exp Clin Med. 2012 Jul 20;37(2):41-6.

12.

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.

Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, Canovatchel W, Meininger G.

Diabetologia. 2013 Dec;56(12):2582-92. doi: 10.1007/s00125-013-3039-1.

13.

Efficacy and safety of initial combination therapy with sitagliptin and pioglitazone in patients with type 2 diabetes: a 54-week study.

Yoon KH, Steinberg H, Teng R, Golm GT, Lee M, O'Neill EA, Kaufman KD, Goldstein BJ.

Diabetes Obes Metab. 2012 Aug;14(8):745-52. doi: 10.1111/j.1463-1326.2012.01594.x.

PMID:
22405352
14.

Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients.

Kubota A, Maeda H, Kanamori A, Matoba K, Jin Y, Minagawa F, Obana M, Iemitsu K, Ito S, Amamiya H, Kaneshiro M, Takai M, Kaneshige H, Hoshino K, Ishikawa M, Minami N, Takuma T, Sasai N, Aoyagi S, Kawata T, Mokubo A, Takeda H, Honda S, Machimura H, Motomiya T, Waseda M, Naka Y, Tanaka Y, Terauchi Y, Matsuba I.

J Diabetes Investig. 2012 Dec 20;3(6):503-9. doi: 10.1111/j.2040-1124.2012.00221.x.

16.
17.

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial.

Aschner P, Chan J, Owens DR, Picard S, Wang E, Dain MP, Pilorget V, Echtay A, Fonseca V; EASIE investigators..

Lancet. 2012 Jun 16;379(9833):2262-9. doi: 10.1016/S0140-6736(12)60439-5.

PMID:
22683131
19.

Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride.

Umayahara R, Yonemoto T, Kyou C, Morishita K, Ogawa T, Taguchi Y, Inoue T.

Endocr J. 2014;61(12):1163-70. doi: 10.1507/endocrj.EJ14-0233.

20.
Items per page

Supplemental Content

Support Center